When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.

O'Sullivan J., Omerdeen I., Psaila B.

Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi-naïve and for those who have previously been treated with a JAKi.

DOI

10.1111/bjh.19929

Type

Journal article

Publication Date

2026-02-01T00:00:00+00:00

Volume

208

Pages

437 - 441

Total pages

4

Keywords

clinical haematology, megakaryocytes, myelofibrosis, myeloproliferative disorder, therapy, Humans, Primary Myelofibrosis, Janus Kinase Inhibitors

Permalink More information Close